All In Biotech

Drug Trial Radar · NCT06446388

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

A Phase II Clinical Study to Evaluate the Efficacy and Safety of QLS31905 and/or QL1706 Combination Chemotherapy for the Treatment of CLDN18.2-Positive Advanced Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Jun 30, 2024

Primary completion

Jun 30, 2026

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of QLS31905 and/or QL1706 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • QLS31905Drug

    Administered as an intravenous infusion.

  • OxaliplatinDrug

    130 mg/m2, intravenous infusion, D1, up to 8 cycles.

  • CapecitabineDrug

    1000 mg/m2, oral, bid, D1-D14

  • GemcitabineDrug

    1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.

  • CisplatinDrug

    25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.

  • QL1706Drug

    5 mg/kg, intravenous infusion,D1

  • Chemotherapy drugDrug

    Standard chemotherapy recommended by guidelines.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.